Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522664 · ClinicalTrials.gov registry record · Phase 1
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01522664 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 53 participants.
The verdict
NCT01522664, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
This multicenter, open-label study will assess the safety and pharmacokinetics of DEDN6526A in patients with metastatic or unresectable melanoma. Cohorts of patients will receive escalating doses of DEDN6526A by intravenous infusion on Day 1 of each 21-day cycle. In the absence of disease progression or unacceptable toxicity, patients may continue to receive DEDN6552A for up to 17 cycles (1 year).
Interventions
- DRUG DEDN6526A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522664
The ClinicalTrials.gov registry entry for NCT01522664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DEDN6526A is the first listed.
NCT01522664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522664 about?
NCT01522664 is a clinical study titled "A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma". This multicenter, open-label study will assess the safety and pharmacokinetics of DEDN6526A in patients with metastatic or unresectable melanoma. Cohorts of patients will receive escalating doses of DEDN6526A by intravenous infusion on Day 1 of each 21-day cycle. In the absence of disease progressio...
What is the current status of trial NCT01522664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2012-03. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01522664?
The interventions under investigation include: DEDN6526A (DRUG).
Who is sponsoring clinical trial NCT01522664?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.